Atossa Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2017 | — | $1.5M | $1.2M |
| Jun 2017 | — | $2.8M | $3.7M |
| Sep 2017 | — | $2.6M | $2.7M |
| Dec 2017 | — | $6.9M | $7.2M |
| Mar 2018 | — | $5.3M | $4.8M |
| Jun 2018 | — | $13.6M | $15.2M |
| Sep 2018 | — | $10.6M | $12.9M |
| Dec 2018 | — | $8.8M | $10.4M |
| Mar 2019 | — | $19.5M | $19.6M |
| Jun 2019 | — | $17.6M | $17.1M |
| Sep 2019 | — | $15.0M | $15.3M |
| Dec 2019 | — | $13.2M | $12.6M |
| Mar 2020 | — | $10.9M | $9.4M |
| Jun 2020 | — | $8.4M | $7.5M |
| Sep 2020 | — | $9.9M | $9.1M |
| Dec 2020 | — | $27.2M | $39.6M |
| Mar 2021 | — | $139.7M | $137.6M |
| Jun 2021 | — | $144.1M | $142.4M |
| Sep 2021 | — | $141.3M | $140.0M |
| Dec 2021 | — | $138.1M | $136.4M |
| Mar 2022 | — | $135.2M | $131.5M |
| Jun 2022 | — | $130.3M | $125.5M |
| Sep 2022 | — | $123.9M | $117.4M |
| Dec 2022 | — | $118.0M | $110.9M |
| Mar 2023 | — | $113.3M | $103.9M |
| Jun 2023 | — | $104.9M | $99.4M |
| Sep 2023 | — | $98.3M | $94.0M |
| Dec 2023 | — | $91.0M | $88.5M |
| Mar 2024 | — | $85.8M | $84.0M |
| Jun 2024 | — | $80.2M | $79.5M |
| Sep 2024 | — | $73.7M | $74.8M |
| Dec 2024 | — | $71.5M | $71.1M |
| Mar 2025 | — | $65.3M | $65.1M |
| Jun 2025 | — | $57.7M | $57.9M |
| Sep 2025 | — | $49.8M | $51.8M |
| Dec 2025 | — | $39.4M | $41.3M |
| Mar 2026 | — | $30.5M | $31.7M |
| Jun 2026 | — | $26.8M | $26.1M |